Initiation of Clinical Study at Lenox Hill
Hospital Seeks to Provide New Option for Treatment of Newly
Diagnosed Unmethylated Glioblastoma
WESTON,
Fla. and NEW YORK,
Sept. 18,
2023 /PRNewswire/ -- Cantex Pharmaceuticals, Inc., a
clinical stage pharmaceutical company focused on developing
transformative therapies for cancer and other life-threatening
medical conditions for which new treatments are urgently needed,
and Lenox Hill Hospital's Department of Neurological Surgery
announced the initiation of a Phase 2 study to assess the safety
and effectiveness of azeliragon in combination with radiation
therapy as a treatment for newly diagnosed unmethylated
glioblastoma.
Glioblastoma is a highly malignant primary brain tumor for which
current therapeutic options provide a limited life extension
benefit. Unmethylated glioblastoma does not respond well to
chemotherapy, further limiting the available treatment options
for patients with this severe form of cancer. New treatments for
glioblastoma are urgently needed.
"We are pleased to announce the initiation of patient enrollment
at Lenox Hill Hospital, a world-class provider of neurosurgical and
cancer treatment, into this important Phase 2 clinical study,"
said Stephen G. Marcus, M.D., Cantex' Chief Executive Officer.
"Azeliragon inhibits activation of a receptor known as 'RAGE' on
the surface of glioblastoma cells. RAGE has been implicated in the
progression of glioblastoma and its resistance to radiation
therapy. In pre-clinical studies, azeliragon enhanced the
effectiveness of radiation therapy. With this study, we seek to
enhance the effectiveness of radiation therapy and delay or prevent
disease progression."
"Through the initiation of this Phase 2 study at Lenox Hill
Hospital, we seek to explore the safety and potential efficacy of
azeliragon as a treatment of unmethylated glioblastoma, which is
less responsive to chemotherapy. This potential therapy may be an
option for patients who lack many other treatment alternatives,"
said John Boockvar, MD, Vice Chair
and Professor of Neurosurgery at Lenox Hill Hospital, and adjunct
Professor at Cold Spring Harbor Laboratory.
About Azeliragon
Azeliragon is an orally administered capsule, taken once daily,
that inhibits interactions of the receptor for advanced glycation
end products (known as RAGE) with certain ligands, including HMGB1
and S100 proteins in the tumor microenvironment. Azeliragon was
discovered by and originally under development for Alzheimer's
disease by vTv Therapeutics Inc. (NASDAQ: VTVT) from whom Cantex
licensed worldwide rights to azeliragon. Clinical safety data from
these trials, involving more than 2000 individuals dosed for
periods up to 18 months, indicate that azeliragon is very well
tolerated. Cantex also has ongoing clinical trials in newly
diagnosed glioblastoma, brain metastasis, neoadjuvant therapy of
breast cancer, metastatic pancreatic cancer, and hospitalized COVID
patients to prevent acute kidney injury. These trials are based on
robust pre-clinical data as well as the extensive clinical safety
information from randomized placebo-controlled clinical trials.
About Cantex Pharmaceuticals, Inc.
Cantex Pharmaceuticals, Inc. is a privately held, clinical stage
pharmaceutical company focused on developing transformative
therapies for cancer and other life-threatening medical conditions
for which new treatments are urgently needed. For more information,
please visit www.cantex.com.
About Northwell Lenox Hill Hospital
Northwell Lenox
Hill Hospital is a 450-bed, fully accredited, acute care hospital
located on Manhattan's Upper East
Side with a national reputation for outstanding patient care and
innovative medical and surgical treatments. U.S. News & World
Report has ranked Lenox Hill among
the nation's best for cardiology and heart surgery; orthopedics;
obstetrics and gynecology; neurology and neurosurgery; geriatrics;
pulmonology and lung surgery; ear, nose and throat; diabetes and
endocrinology; and cancer. In addition, the hospital received
designations from U.S. News for its performance in 19 procedures
and conditions. Lenox Hill was also
named among 'America's 50 Best Hospitals' by Healthgrades, placing
it in the top 1 percent of all hospitals nationwide. For more
information, go to www.lenoxhill.northwell.edu.
About vTv Therapeutics Inc.
vTv Therapeutics Inc. is a
clinical stage biopharmaceutical company focused on developing
oral, small molecule drug candidates, led by cadisegliatin (TTP399)
for the treatment of type 1 diabetes. To learn more please visit
vtvtherapeutics.com.
Contact Data:
Cantex Pharmaceuticals, Inc.
Stephen G. Marcus, M.D.
+1 954-315-3660
info@cantex.com
Juan F. Rodriguez
+1 954-315-3660
info@cantex.com
Tiberend Strategic Advisors, Inc.
Investors
Daniel
Kontoh-Boateng
(862) 213-1398
dboateng@tiberend.com
Media
Casey McDonald
+1 646-577-8520
cmcdonald@tiberend.com
Lenox Hill Hospital
Tamika Wong
+1 212-434-4836
Twong4@northwell.edu
View original content to download
multimedia:https://www.prnewswire.com/news-releases/cantex-pharmaceuticals-and-lenox-hill-hospital-announce-initiation-of-a-phase-2-study-of-rage-inhibitor-azeliragon-as-a-front-line-treatment-for-unmethylated-glioblastoma-301930043.html
SOURCE Cantex Pharmaceuticals, Inc.
